BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bomedemstat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bomedemstat\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06079879-2890@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06079879)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: A St
 udy of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (
 BAT) in Participants With Essential Thrombocythemia and an Inadequate Resp
 onse or Intolerance of Hydroxyurea (MK-3543-006)\nEstimated primary comple
 tion: 14 July 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 omedemstat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06079879
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456346-2890@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06456346)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: Bome
 demstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)\nEstima
 ted primary completion: 28 September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bomedemstat#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06456346
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424950-2890@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Bomedemstat: Phase 2 readout est. (NCT07424950)
DESCRIPTION:Bomedemstat\, phase 2.\nStudy: Bomedemstat (IMG-7289) in Combin
 ation With Momelotinib in Patients With Myelofibrosis\nEstimated primary c
 ompletion: 1 November 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bomedemstat#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07424950
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722611-2890@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20320625
DTEND;VALUE=DATE:20320626
SUMMARY:Bomedemstat: Phase 2/3 readout est. (NCT07722611)
DESCRIPTION:Bomedemstat\, phase 2/3.\nStudy: A Clinical Trial of Bomedemsta
 t in Participants With Polycythemia Vera (MK-3543-025).\nEstimated primary
  completion: 25 June 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bomedemstat#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07722611
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351631-2890@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20341204
DTEND;VALUE=DATE:20341205
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06351631)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: A St
 udy to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)\nEstimate
 d primary completion: 4 December 2034. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bomedemstat#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06351631
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
